Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.
about
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsPopulation pharmacokinetics of bevacizumab in cancer patients with external validationOptimal combination of antiangiogenic therapy for hepatocellular carcinomaAntiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyAnti-vascular endothelial growth factor therapy in breast cancerFirst-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineOptimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trialsPhase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.Methylation-mediated gene silencing as biomarkers of gastric cancer: a review.Ramucirumab: preclinical research and clinical development.A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursUse of bevacizumab as a first-line treatment for metastatic breast cancer.Window of opportunity: A new insight into sequential bevacizumab and paclitaxel in two cases of metastatic triple-negative breast cancer.High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer.Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-studyEfficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line settingA plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancerLoss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancerChanging molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomesTherapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review)Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update.Prior exposure to chemotherapy: a marker of sensitivity and selection for antiangiogenic therapy in breast cancer?Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.Advances in the approach to novel drug clinical development for breast cancer.Clinical experience with ramucirumab : outcomes in breast cancer.VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.Resistance to antiangiogenic therapies.Bevacizumab: a review of its use in advanced cancer.Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.Pharmacogenetics and breast cancer management: current status and perspectives.VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.Metastatic breast cancer: The Odyssey of personalization.
P2860
Q26773795-71DDAD94-5273-44CC-8028-A7065EFC3143Q26779580-41D2D6F5-5DCD-4E75-A05A-2AEBA4C5136DQ26799458-67CC72D2-8E23-4E85-AE4E-73E19A3D5B55Q26822432-1B6F07A0-DD78-411E-BBB1-5C7A4C2D6668Q26993238-FC80212F-4681-4386-8CEA-735E7F932D8AQ26999473-5C429573-E230-4AB1-9DA3-297D6010B769Q30657829-AF6EA29A-B2D6-4089-B5D5-15A72EC763DCQ33770680-7364A3D1-F981-4E8F-B999-68AD12FA2474Q33817285-68AE5CF3-A979-4D6A-8B7B-ABB4C2A47B6CQ33879154-C5B5FB48-1BA7-4500-BA5C-DE50E065DF01Q33921891-9BFC1B85-1952-45CD-A4F4-EC0B71667C68Q34168437-EBC9F71B-1BEE-43A2-B1BB-2355EFC24B04Q34446310-8ABC7592-030F-4C47-88E9-F54F8CA430B4Q35001280-2F305690-A85C-4951-8DF1-046AE496B4EDQ35223622-E00BAC35-C48F-4B73-B292-6F4CBD167E96Q35274974-C6868926-3367-4B20-990C-673C58A439F3Q35445151-F305AA1A-E9F0-4A93-93FC-30E476A82EE5Q35942949-EC5F409C-8D6F-412C-A788-D7685D41751FQ35947983-C5BC91F7-6E6C-468F-90B4-F73016B56FA2Q36207673-3EF30209-B4BD-420C-AD1F-A7ADC2DC01B5Q36209477-EDA87E9D-126E-4D8C-BC41-14A32555392CQ36286704-494D4B85-0139-4CCC-82F8-7E5C6D614CC8Q36295068-64DF2B03-B09C-4EB0-8F26-B8A49331B332Q36333585-08CD8E79-B741-496A-820E-CE1CB64414FEQ37083038-A0C8D616-A445-4AC9-9D09-86D5BF6E61DAQ37174919-F8CE9549-0AF1-41C5-9ECB-CB2D5BCD50DEQ37265655-9B7BBF28-3116-43AA-83E0-F829340131EAQ37631514-1EB027C6-6632-4243-BA73-2781A4EB3790Q38148602-1D8A310A-EE37-42D9-8C9B-9E5948F91752Q38168926-616103A3-2D79-4673-BCD4-4093A40D9CA5Q38188598-094A709F-8956-4E06-92AC-7BEA8C990D22Q38206546-57F4D9AD-0694-4F9E-8C4F-396FDDFE0005Q38228982-C4DFD73A-90C7-4393-A8D5-37C9774175C8Q38232368-C5ECE4C8-326C-4254-A4CC-E751DFE78584Q38232852-669D06CF-BEF5-4ABE-8B78-8AEE898FD43DQ38260176-D2F0D388-005B-4FA6-9471-FA4424E7F3D8Q38308001-8466450E-5C64-4EF3-A35E-C346A9278D01Q38358816-07058A66-687E-444E-9919-4D4543B8D558Q38462868-AE46F8E4-1F8E-4B7C-A841-C06C5CB23AEBQ38901163-062D210D-F53D-42F5-826B-126E29B45858
P2860
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Biomarker results from the AVA ...... tive metastatic breast cancer.
@en
type
label
Biomarker results from the AVA ...... tive metastatic breast cancer.
@en
prefLabel
Biomarker results from the AVA ...... tive metastatic breast cancer.
@en
P2093
P2860
P921
P356
P1476
Biomarker results from the AVA ...... ative metastatic breast cancer
@en
P2093
L Provencher
P R Delmar
S J Scherer
S L de Haas
P2860
P2888
P304
P356
10.1038/BJC.2013.69
P407
P577
2013-02-19T00:00:00Z